rapid
reliabl
diagnosi
influenza
essenti
identif
contagi
patient
effect
patient
manag
nearpati
assay
allow
establish
diagnosi
within
minut
young
children
studi
aim
evalu
nearpati
assay
relat
patient
age
total
patient
laboratoryconfirm
influenza
viru
infect
diagnos
within
prospect
cohort
studi
includ
cryopreserv
nasopharyng
swab
collect
patient
test
four
nearpati
assay
binax
influenza
b
quick
sinflu
ab
influa
b
respistrip
actim
influenza
b
main
outcom
measur
sensit
nearpati
assay
relat
age
patient
binax
quick
sinflu
influa
b
respistrip
actim
assay
overal
sensit
respect
estim
sensit
influenza
viru
detect
nasopharyng
swab
children
year
age
decreas
patient
year
age
logist
regress
sensit
influa
b
respistrip
actim
assay
decreas
significantli
increas
age
p
p
respect
logist
regress
trend
decreas
observ
binax
assay
p
logist
regress
low
sensit
quick
sinflu
assay
similar
children
adult
less
onefourth
diagnos
influenza
viru
infect
identifi
elderli
patient
use
nearpati
assay
consequ
nearpati
assay
limit
valu
confirm
diagnosi
influenza
clinic
suspect
adult
antivir
therapi
addit
diagnost
procedur
withheld
basi
neg
nearpati
assay
result
particularli
adult
patient
estim
hospit
death
attribut
influenza
annual
usa
alon
elderli
patient
affect
influenzarel
death
hospit
use
health
servic
record
mostli
patient
year
age
viru
spread
particularli
rapidli
care
home
potenti
affect
resid
accur
rapid
diagnosi
influenza
essenti
identif
contagi
patient
effect
manag
case
influenza
manag
decis
regard
infect
control
referr
special
unit
use
addit
diagnost
procedur
administr
antivir
therapi
made
point
first
contact
patient
antivir
drug
oseltamivir
zanamivir
highli
effect
influenza
b
virus
must
administ
soon
possibl
least
within
first
h
onset
acut
respiratori
diseas
effect
reliabl
identif
case
influenza
within
short
time
frame
challeng
sensit
specif
clinic
diagnosi
influenza
low
respect
even
peak
flu
season
laboratorybas
assay
diagnosi
influenza
eg
detect
viru
viral
genom
respiratori
secret
via
viru
cultur
influenza
virusspecif
pcr
highli
sensit
specif
test
result
howev
usual
becom
avail
h
sampl
collect
sever
day
onset
diseas
nearpati
diagnost
assay
provid
result
within
min
almost
commerci
assay
current
avail
diagnosi
influenza
specif
assay
well
valu
test
sensit
state
manufactur
product
inform
differ
sometim
consider
describ
investigatoriniti
studi
previous
observ
sensit
laboratorybas
diagnost
assay
detect
influenza
viru
viral
particl
respiratori
specimen
decreas
significantli
increas
age
patient
manufactureriniti
evalu
nearpati
assay
knowledg
concern
exclus
respiratori
specimen
collect
young
children
inform
provid
binax
inc
cori
bioconcept
medix
biochemica
denka
seiken
howev
studi
reveal
clearli
lower
sensit
assay
includ
sampl
age
group
thu
suspect
patient
age
may
influenc
detect
rate
achiev
nearpati
assay
therefor
aim
present
studi
evalu
parallel
sever
differ
nearpati
assay
test
respiratori
specimen
children
adult
laboratoryconfirm
influenza
viru
infect
virolog
surveil
respiratori
viru
activ
austria
base
respiratori
specimen
collect
sentinel
physician
physician
inpati
outpati
hospit
unit
gener
practition
paediatrician
throughout
austria
within
two
surveil
systemsth
diagnost
influenza
network
austria
dino
respiratori
network
rnw
inclus
criterion
dino
influenzalik
ill
acut
onset
fever
respiratori
constitut
symptom
rnw
clinic
diagnosi
acut
respiratori
tract
infect
includ
rhiniti
bronchiti
pneumonia
two
surveil
system
includ
patient
age
group
acut
respiratori
tract
infect
nasopharyng
swab
taken
experienc
physician
swab
taken
nose
throat
patient
swab
content
tranfer
transport
medium
consist
minim
essenti
medium
mem
gibco
life
technolog
lofer
austria
discard
thereaft
clinician
particip
two
surveil
system
provid
transport
medium
clinic
institut
virolog
medic
univers
vienna
immedi
deliveri
clinic
sampl
vortex
vigor
dilut
mem
split
aliquot
screen
influenza
b
virus
viru
isol
rtpcr
present
investig
influenza
sampl
collect
period
epidem
activ
influenza
winter
season
test
cryopreserv
later
analysi
sampl
frozen
thaw
present
investig
sampl
collect
patient
younger
year
older
year
includ
separ
patient
two
age
group
done
practic
reason
two
surveil
network
dino
rnw
highest
consult
rate
observ
patient
younger
year
older
year
influenza
season
aim
therefor
optim
project
compar
assess
nearpati
assay
age
group
purpos
standard
influenza
virusposit
sampl
includ
virolog
diagnosi
establish
patient
influenza
virusspecif
pcr
confirm
viru
isol
viru
isol
tissu
cultur
type
isol
viru
isol
tissu
cultur
type
isol
carri
madindarbi
canin
kidney
cell
american
type
cultur
collect
manassa
va
usa
accord
standard
procedur
influenza
viru
strain
isol
studi
period
type
subtyp
describ
previous
viral
genom
rna
detect
clinic
sampl
nest
pcr
assay
describ
previous
brief
viral
rna
extract
clinic
sampl
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
revers
transcript
two
step
nest
pcr
influenza
viru
typespecif
primer
bind
highli
conserv
region
influenza
viru
genom
code
nonstructur
protein
use
pcr
experi
includ
two
five
posit
control
sever
neg
control
two
three
respiratori
virusposit
specimen
respiratori
syncyti
viru
enterovirus
rhinovirus
coronaviru
parainfluenza
virus
adenovirus
interpos
sampl
test
quantif
influenza
virusspecif
rna
clinic
sampl
done
describ
previous
inhous
elisa
use
detect
influenza
viru
antigen
carri
describ
previous
commerci
avail
rapid
diagnost
test
screen
test
influenza
b
viru
infect
provid
result
within
min
test
immunoassay
detect
influenza
viral
antigen
respiratori
specimen
use
virusspecif
antibodi
may
also
refer
rapid
test
pointofcar
test
offici
austrian
repres
manufactur
assay
nearpati
diagnosi
influenza
n
invit
particip
present
studi
donat
kit
suffici
number
test
clinic
specimen
children
clinic
specimen
adult
tabl
summar
select
characterist
four
rapid
assay
evalu
present
studi
accord
manufactur
product
inform
nasopharyng
swab
transport
medium
may
use
without
signific
loss
sensit
specif
assay
total
clinic
specimen
use
test
quantiti
equal
averag
volum
nasopharyng
secret
collect
standard
cotton
swab
medix
biochemica
denka
seiken
person
commun
clinic
specimen
patient
includ
evalu
four
assay
volum
sampl
suffici
test
four
assay
therefor
sampl
assign
randomli
within
two
age
group
four
diagnost
assay
allow
equal
number
sampl
test
four
assay
logist
regress
use
analys
relationship
test
result
obtain
four
nearpati
diagnost
assay
patient
age
receiv
oper
characterist
roc
curv
use
assess
extent
concentr
influenza
virusspecif
rna
clinic
sampl
may
associ
falseneg
result
nearpati
assay
comparison
nearpati
assay
result
respect
concentr
influenza
viru
carri
use
mannwhitney
utest
analys
pvalu
consid
statist
signific
statist
analys
perform
use
commerci
softwar
spss
spss
inc
chicago
il
usa
clinic
specimen
use
present
evalu
nearpati
assay
posit
influenza
purpos
standard
correspond
season
predomin
influenza
studi
period
http
wwweissorg
specimen
collect
patient
year
age
mean
age
children
year
standard
deviat
sd
year
adult
year
sd
year
seven
patient
younger
year
older
year
binax
influenza
b
quick
sinflu
ab
influa
b
respistrip
actim
influenza
b
overal
sensit
respect
shown
fig
sensit
three
sensit
assay
decreas
increas
age
patient
wherea
low
sensit
quick
sinflu
ab
assay
constant
throughout
age
young
children
elderli
patient
estim
probabl
detect
influenza
viru
clinic
specimen
test
posit
accord
rtpcr
children
year
age
decreas
patient
year
age
sensit
nearpati
assay
compar
high
overal
sensit
influa
b
respistrip
actim
influenza
b
decreas
significantli
increas
age
tabl
trend
lower
sensit
adult
observ
also
binax
influenza
b
order
evalu
sensit
nearpati
assay
standard
condit
celladapt
viru
stock
prepar
influenza
anew
test
three
four
nearpati
assay
comparison
inhous
antigenelisa
inhous
rtpcr
assay
vitro
evalu
quick
sinflu
ab
assay
possibl
manufactur
provid
kit
test
prepar
dilut
tenfold
step
mem
vortex
vigor
separ
five
aliquot
test
five
assay
experi
detect
limit
three
nearpati
assay
inhous
antigenelisa
rang
tissu
cultur
infect
dose
tcid
ml
wherea
rtpcr
vitro
sensit
tcid
ml
tabl
vitro
sensit
actim
influenza
b
assay
one
log
titr
higher
influenza
strain
use
sensit
nearpati
assay
sensit
assay
use
lower
influenza
influenza
b
viru
strain
use
clinic
sampl
suffici
volum
avail
n
addit
test
use
quantit
influenza
virusspecif
rtpcr
comparison
qualit
result
obtain
nearpati
assay
posit
result
nearpati
assay
associ
significantli
higher
concentr
influenza
viru
rna
clinic
sampl
neg
result
tabl
roc
cutoff
point
predict
sensit
nearpati
assay
detect
influenza
viru
clinic
sampl
similar
vitro
sensit
observ
test
viru
stock
prepar
influenza
viru
compar
tabl
area
roc
curv
posit
nearpati
assay
result
similar
four
assay
rang
fig
low
sensit
nearpati
assay
may
suspect
basi
previou
studi
present
studi
demonstr
unambigu
first
time
effect
nearpati
assay
diagnosi
influenza
viru
infect
decreas
significantli
increas
age
patient
low
sensit
nearpati
assay
diagnosi
influenza
comparison
viru
isol
rtpcr
allow
reliabl
exclus
diagnosi
influenza
present
studi
support
belief
antivir
therapi
addit
diagnost
procedur
withheld
case
influenza
clinic
suspect
basi
neg
nearpati
assay
particularli
adult
patient
hand
high
specif
nearpati
assay
togeth
advantag
result
avail
within
min
may
provid
import
inform
clinic
evalu
patient
acut
respiratori
ill
provid
result
nearpati
assay
posit
reliabl
rapid
identif
influenza
case
particular
import
elderli
patient
age
group
year
high
risk
sever
cours
influenza
influenzarel
death
occur
age
group
estim
risk
influenzarel
hospit
per
individu
influenza
season
highli
effect
antivir
drug
avail
treatment
influenza
must
administ
within
h
onset
diseas
effect
influenza
virus
respiratori
syncyti
viru
cocircul
frequent
influenza
virus
caus
signific
diseas
burden
also
elderli
patient
clinic
featur
difficult
distinguish
influenza
use
nearpati
assay
particularli
low
elderli
consequ
consider
number
patient
treat
unnecessarili
ineffect
antivir
antibacteri
drug
expos
radiat
due
addit
diagnost
procedur
therefor
import
annual
vaccin
influenza
elderli
patient
caregiv
overemphas
previou
studi
detect
rate
influenza
virus
clearli
lower
test
respiratori
specimen
adult
test
specimen
young
children
even
use
highli
sensit
assay
rtpcr
result
previou
evalu
nearpati
assay
sensit
regard
patient
age
discord
fader
note
clear
decreas
assay
sensit
increas
age
wherea
weinberg
walker
although
studi
evalu
assay
binax
binax
inc
portland
usa
respiratori
specimen
use
heterogen
nasal
wash
nasal
aspir
bronchoalveolar
lavag
differ
two
studi
adult
nasal
wash
conveni
collect
nasopharyng
aspir
dilut
effect
inher
techniqu
sampl
collect
result
lower
detect
rate
strength
present
studi
use
compar
sampl
clinic
specimen
collect
ident
techniqu
experienc
welltrain
physician
use
standard
sampl
kit
furthermor
vitro
evalu
nearpati
assay
sensit
use
viru
stock
prepar
could
confirm
determin
influenza
viru
rna
concentr
clinic
sampl
featur
reduc
potenti
bia
support
notion
find
gener
present
studi
also
limit
sampl
posit
influenza
virus
test
purpos
standard
conclus
drawn
concern
sensit
nearpati
assay
influenza
b
virus
present
studi
vitro
sensit
nearpati
assay
differ
influenza
b
virus
direct
comparison
vitro
sensit
nearpati
assay
rtpcr
made
caution
use
cell
culturegrown
influenza
strain
cell
cultur
prepar
contain
consider
amount
defect
viru
particl
differ
structur
particl
may
detect
use
nearpati
assay
rtpcr
degrad
viru
particl
follow
differ
kinet
cell
cultur
human
host
furthermor
assay
evalu
retrospect
virolog
laboratori
previou
studi
laboratori
set
allow
standard
interassay
comparison
transfer
respiratori
secret
medium
use
preserv
viru
solubil
mucu
add
dilut
step
may
reduc
detect
rate
achiev
nearpati
assay
present
investig
preserv
nasopharyng
swab
transport
medium
result
final
dilut
one
log
titr
dilut
effect
explain
differ
sensit
observ
age
group
differ
among
four
nearpati
assay
nevertheless
effect
nearpati
assay
diagnosi
influenza
viru
infect
may
expect
somewhat
higher
bedsid
test
perform
conclus
sensit
nearpati
assay
significantli
lower
influenza
virusspecif
rtpcr
also
significantli
affect
patient
age
antivir
therapi
addit
diagnost
procedur
withheld
basi
nearpati
assay
neg
result
particularli
adult
patient
influenza
clinic
suspect
high
specif
nearpati
assay
howev
posit
test
result
may
help
make
manag
decis
includ
concern
administr
antivir
therapi
